<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2714">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380818</url>
  </required_header>
  <id_info>
    <org_study_id>IPACOVID</org_study_id>
    <nct_id>NCT04380818</nct_id>
  </id_info>
  <brief_title>Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19</brief_title>
  <official_title>Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19: Multi-central Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo de Investigación Clínica en Oncología Radioterapia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Madrid Sanchinarro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital del Mar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari Sant Joan de Reus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo de Investigación Clínica en Oncología Radioterapia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low radiation doses produce anti-inflammatory effects, which may be useful in the treatment
      of respiratory complications of COVID-19. This type of treatment is non-invasive and
      therefore, a priori, it can be used in all types of patients.

      Main objective: To evaluate the efficacy of low-dose lung irradiation as an adjunctive
      treatment in interstitial pneumonia in patients with COVID-19 by improving the PAFI O2 by 20%
      measured 48h after treatment with respect to the pre baseline measurement. -irradiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: This is a prospective multicenter study in 2 phases:

        1. Exploratory phase. It will include 10 patients, to assess the feasibility and efficacy
           of low-dose lung irradiation. If a minimum efficiency of 30% is not achieved, the study
           will not be continued.

        2. Comparative phase in two groups, a control group, which will only receive
           pharmacological treatment, and an experimental one. It will include 96 patients, the
           allocation will be 1: 2, that is, 32 in the control arm and 64 in the experimental arm,
           which will receive low-dose lung irradiation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 4, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of low-dose pulmonary irradiation assessed by change in PAFI O2 by 20%</measure>
    <time_frame>Day 2 after interventional radiotherapy</time_frame>
    <description>To evaluate the efficacy of low-dose pulmonary irradiation as an adjunctive treatment in interstitial pneumonia in patients with COVID-19 by improving the PAFI O2 by 20% measured 48h after treatment with respect to baseline pre-irradiation measurement. .
In cases of impossibility the SaFiO2 will be determined</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>Day 30 and day 90 after interventional radiotherapy</time_frame>
    <description>Lung toxicity measured according to CTCAEv5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the radiological image</measure>
    <time_frame>Days 7 and day 30 after interventional radiotherapy</time_frame>
    <description>Chest CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>Day 15 and Day 30 after interventional radiotherapy</time_frame>
    <description>Death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of pro-inflammatory interleukins</measure>
    <time_frame>Days 1, day 4 and day 7 after interventional radiotherapy</time_frame>
    <description>Interleukins IL-6, IL-10, IL-1, IL-2, IL-8 (pg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of trasforming growth factor (TGF-b)</measure>
    <time_frame>Days 1, day 4 and day 7 after interventional radiotherapy</time_frame>
    <description>TGF-β (ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of tumor necrosis factor alpha (TNF-a)</measure>
    <time_frame>Days 1, day 4 and day 7 after interventional radiotherapy</time_frame>
    <description>TNF-α (pg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determining overexpression of pro-inflammatory selectin</measure>
    <time_frame>Days 1, day 4 and day 7 after interventional radiotherapy</time_frame>
    <description>Overexpression of L-, E-, and P-selectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determining cell adhesion molecules (CAMs)</measure>
    <time_frame>Days 1, day 4 and day 7 after interventional radiotherapy</time_frame>
    <description>Overexpression of ICAM-1, VCAM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of marker of oxidative stress PON-1</measure>
    <time_frame>Days 1, day 4 and day 7 after interventional radiotherapy</time_frame>
    <description>PON-1(paraoxonase and arylesterase activity) (IU/ml)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Pneumonia, Viral</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a control group only receive pharmacological treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>an experimental group will receive low-dose lung irradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Low-dose radiotherapy</intervention_name>
    <description>Bilateral low-dose lung irradiation: 0.5 Gy in a single fraction. Optionally, additional 0.5 Gy fraction 48h later</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine Sulfate</intervention_name>
    <description>200 mg/12h for 5 days</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Dolquine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir/lopinavir</intervention_name>
    <description>400/100 mg/12h for 7-10 days</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Kaletra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab Injection [Actemra]</intervention_name>
    <description>600 mg/day for 1-2 doses</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Actemra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>500 mg/24h for 3 days</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid</intervention_name>
    <description>Corticosteroids (methylprednisolone/dexamethasone/prednisone)</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low molecular weight heparin</intervention_name>
    <description>low molecular weight heparin (LMWH) in prophylaxis of venous thromboembolism</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oxygen supply</intervention_name>
    <description>Oxygen</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;=18 years old

          -  Moderate to severe COVID-19 pneumonia with fewer than 8 days of symptom onset and
             currently receiving standard medication for COVID-19 at appropriate doses

          -  PAFIO2 of less than 300 mmHg or SaFI02 &lt;315 mmHg

          -  Patients who are not candidates for admission to the Intensive Care Unit due to age,
             concomitant diseases or general condition.

          -  One of the following conditions:

               -  or IL6 greater than 40

               -  or PCR&gt; 100mg / l

                    -  D-dimer greater than 1500ng / ml

                    -  Suspected cytokine release syndrome

          -  Have read the information sheet and signed the informed consent

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Failure to meet the inclusion criteria

          -  Leukopenia &lt;1000

          -  Pregnancy

          -  Not understanding or refusing the purpose of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angel Montero, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Madrid Sanchinarro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manel Algara, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Merirxell Arenas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Sant Joan de Reus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ANGEL MONTERO, Md, PhD</last_name>
    <phone>+34667767601</phone>
    <email>angel.monteroluis@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MERITXELL ARENAS, MD, PhD</last_name>
      <email>meritxell.arenas@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MANEL ALGARA, MD, PhD</last_name>
      <email>MAlgara@parcdesalutmar.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Montero, MD, PhD</last_name>
      <phone>+34915629949</phone>
      <email>amontero@hmhospitales.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020 March-April,;34(2):327-331. doi: 10.23812/CONTI-E.</citation>
    <PMID>32171193</PMID>
  </reference>
  <reference>
    <citation>Rödel F, Frey B, Manda K, Hildebrandt G, Hehlgans S, Keilholz L, Seegenschmiedt MH, Gaipl US, Rödel C. Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose x-irradiation. Front Oncol. 2012 Sep 25;2:120. doi: 10.3389/fonc.2012.00120. eCollection 2012.</citation>
    <PMID>23057008</PMID>
  </reference>
  <reference>
    <citation>Arenas M, Sabater S, Hernández V, Rovirosa A, Lara PC, Biete A, Panés J. Anti-inflammatory effects of low-dose radiotherapy. Indications, dose, and radiobiological mechanisms involved. Strahlenther Onkol. 2012 Nov;188(11):975-81. doi: 10.1007/s00066-012-0170-8. Epub 2012 Aug 22. Review.</citation>
    <PMID>22907572</PMID>
  </reference>
  <reference>
    <citation>Arenas M, Gil F, Gironella M, Hernández V, Biete A, Piqué JM, Panés J. Time course of anti-inflammatory effect of low-dose radiotherapy: correlation with TGF-beta(1) expression. Radiother Oncol. 2008 Mar;86(3):399-406. Epub 2007 Nov 26.</citation>
    <PMID>18031855</PMID>
  </reference>
  <reference>
    <citation>Lödermann B, Wunderlich R, Frey S, Schorn C, Stangl S, Rödel F, Keilholz L, Fietkau R, Gaipl US, Frey B. Low dose ionising radiation leads to a NF-κB dependent decreased secretion of active IL-1β by activated macrophages with a discontinuous dose-dependency. Int J Radiat Biol. 2012 Oct;88(10):727-34. Epub 2012 May 22.</citation>
    <PMID>22545750</PMID>
  </reference>
  <reference>
    <citation>Calabrese EJ, Dhawan G. How radiotherapy was historically used to treat pneumonia: could it be useful today? Yale J Biol Med. 2013 Dec 13;86(4):555-70.</citation>
    <PMID>24348219</PMID>
  </reference>
  <reference>
    <citation>Calabrese EJ, Dhawan G, Kapoor R, Kozumbo WJ. Radiotherapy treatment of human inflammatory diseases and conditions: Optimal dose. Hum Exp Toxicol. 2019 Aug;38(8):888-898. doi: 10.1177/0960327119846925. Epub 2019 May 6. Review.</citation>
    <PMID>31060383</PMID>
  </reference>
  <reference>
    <citation>Kirkby C, Mackenzie M. Is low dose radiation therapy a potential treatment for COVID-19 pneumonia? Radiother Oncol. 2020 Jun;147:221. doi: 10.1016/j.radonc.2020.04.004. Epub 2020 Apr 6.</citation>
    <PMID>32342871</PMID>
  </reference>
  <reference>
    <citation>Jean-Marc Cosset, Éric Deutsch, Louis Bazire, Jean-Jacques Mazeron, Cyrus Chargari, Irradiation pulmonaire à faible dose pour l'orage de cytokines du covid-19: pourquoi pas?, Cancer/Radiothérapie, 2020, , ISSN 1278-3218, https://doi.org/10.1016/j.canrad.2020.04.003.</citation>
  </reference>
  <reference>
    <citation>Dhawan G, Kapoor R, Dhawan R, Singh R, Monga B, Giordano J, Calabrese EJ. Low dose radiation therapy as a potential life saving treatment for COVID-19-induced acute respiratory distress syndrome (ARDS). Radiother Oncol. 2020 Jun;147:212-216. doi: 10.1016/j.radonc.2020.05.002. Epub 2020 May 8. Review.</citation>
    <PMID>32437820</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID 19</keyword>
  <keyword>RADIATION</keyword>
  <keyword>Anti-inflammatory effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual epidemiological and clinical data will be shared after recruitment is complete.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Protocol/ICF from approval Individual epidemiological and clinical data after recruitment is complete.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

